[Federal Register Volume 59, Number 48 (Friday, March 11, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-5673]
[[Page Unknown]]
[Federal Register: March 11, 1994]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Advisory Committee Meeting; Amendment of Notice
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
amendment to the meeting of the Cardiovascular and Renal Drugs Advisory
Committee, which is scheduled for March 24 and 25, 1994. This meeting
was announced in the Federal Register of February 25, 1994 (59 FR 9219
at 9220). The amendment is being made to change both the starting times
of the meetings for March 24 and 25, 1994, and revise the agenda for
the open committee discussion of the meeting of March 25, 1994. Both
amendments will be announced at the beginning of the open portion of
the meeting.
FOR FURTHER INFORMATION CONTACT:
Joan C. Standaert, Center for Drug Evaluation and Research, Food
and Drug Administration, 234 Summit St., Toledo OH 43604, 419-259-6211
or
Valerie M. Mealy, Center for Drug Evaluation and Research (HFD-9),
Food and Drug Administration, 5600 Fishers Lane, Rockville MD 20857,
301-443-4695.
SUPPLEMENTARY INFORMATION: In the Federal Register of February 25, 1994
(59 FR 9219 at 9220), FDA announced that a meeting of the
Cardiovascular and Renal Drugs Advisory Committee would be held on
March 24 and 25, 1994. On page 9220, column 1, the ``Date, time, and
place,'' ``Type of meeting and contact person,'' and the ``Open
committee discussion'' portions of this meeting are amended to read as
follows:
Date, time, and place. March 24 and 25, 1994, 9 a.m., conference
rms. D and E, Parklawn Bldg., 5600 Fishers Lane, Rockville, MD.
Type of meeting and contact person. Open public hearing, March 24,
1994, 9 a.m. to 10 a.m., unless public participation does not last that
long; open committee discussion, 10 a.m. to 5 p.m.; open committee
discussion, March 25, 1994, 9 a.m. to 5 p.m.
Open committee discussion. On March 24, 1994, the committee will
discuss new drug application (NDA) 20-390 (vesnarinone),
Arkin, Otsuka America Pharmaceutical, for congestive heart
failure, and NDA 19-151/S-002 (propafenone), Rythmol, Knoll
Pharmaceuticals, for prophylaxis of paroxysmal supraventricular
tachycardia and paroxysmal atrial fibrillation and flutter. On March
25, 1994, the committee will continue its discussion on NDA 19-151/S-
002.
Dated: March 7, 1994.
Jane E. Henney,
Deputy Commissioner for Operations.
[FR Doc. 94-5673 Filed 3-10-94; 8:45 am]
BILLING CODE 4160-01-F
